Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery.
The advent of pathotropic (disease-seeking) targeting has transported genetic medicine across the threshold of history with the progressive clinical validation of Rexin-G, a tumor-targeted nanosized anti-cancer agent. Achieving noteworthy single-agent efficacy and survival benefits in otherwise intractable cancers, the molecular biotechnology platform has stimulated intense interest in the underlying mechanisms-of-action. This report exhibits the effective localization of Rexin-G nanoparticles within a metastatic liver lesion, as observed upon its surgical excision.
Hall
Frederick L
FL
Oncology Research Unit, Epeius Biotechnologies Corporation, San Marino, CA 91108, USA.
Levy
John P
JP
Reed
Rebecca A
RA
Petchpud
Wasinee N
WN
Chua
Victoria S
VS
Chawla
Sant P
SP
Gordon
Erlinda M
EM
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D056766:Cyclin G1 / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D053758:Nanoparticles / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010957:Plasmids; D012190:Retroviridae
D000970:Antineoplastic Agents; C534702:CCNG1 protein, human; D056766:Cyclin G1